Influence of scientific research on policy: a funder’s perspective

Chonnettia Jones, Ph.D.
Director of Insight & Analysis
Our origins

Founder Sir Henry Wellcome was an entrepreneur, collector and philanthropist.

On his death in 1936, his will established a charity for "the advancement of medical and scientific research to improve mankind's wellbeing".
The framework sets out 9 shared ambitions that express ‘what success looks like’ to Wellcome.

We aspire to improve health for everyone by helping great ideas to thrive.

We will achieve this by:

• Maximising the potential of research to improve health.
• Delivering innovations that prevent or treat health problems.
• Engaging society to shape choices that lead to better health.

We hold ourselves accountable to society for delivering Wellcome’s mission, while using our independence for public benefit.
Case Study 1: Treatment for Malaria
Artesunate-based Malaria Mono- and Combination Therapy

1979
First evaluations of artemisinin derivatives in Africa supported by Wellcome as part of Mahidol Oxford Tropical Medicine Research Unit (MORU).

1992
Trial shows artemisinin compounds to be capable of treating malaria.

1994-8
MORU studies show that artemisinin derivatives act extremely rapidly and reduce transmission potential of malaria. MORU pioneers use of combination therapies (ACT) to reduce risk of treatment failure, parasite resistance and side effects in patients, compared with monotherapy.

2005
First edition WHO malaria treatment guidelines recommend artemesunate as first-line treatment, in combination therapy for uncomplicated falciparum malaria, as monotherapy for severe falciparum malaria in adults.

2006
The Global Fund and Affordable Medicines Facility bankrolls or subsidises distribution of artemisinin combination therapies in public and private sectors.

2008
Trial (AQUAMAT) in African children with severe malaria shows artemesunate monotherapy reduces mortality by 22% vs quinine. Trial supported by Wellcome through Project Grants to Prof. Nick White and core funding of MORU.

2010
WHO revise malaria guidelines to extend recommendation of artemesunate monotherapy as first-line treatment in management of severe malaria to include children, citing AQUAMAT.
Case Study 2: Psychological therapies
Wellcome provides flexible funding for Prof. David Clark through Principal Research Fellowships and Project Grant for the design and testing of psychological therapies.

Knowledge + Clinical Studies + Infrastructure

1991
Wellcome contribution

Contributions of others

Outcomes

Impact

1993

In addition to Prof. David Clark's work, Wellcome contributes funding for research into other psychological therapies subsequently offered by IAPT.

2000

Wellcome supports 'Psychology Research Building' to house David Clark's Anxiety Disorders Group moving from Oxford to Kings College.

2007

UK government announces NHS will pioneer the world's largest publicly funded programme of psychological therapies – IAPT, designed, implemented and monitored by Prof. David Clark, delivering many therapies developed through Wellcome funding.

2009

IAPT service launches with 100,000 patients in first year, with expectations to scale up.

2016

After initial launch, IAPT scales up. In 2016, 940,000 patients enter treatment.

2016

UK government announces funding uplift for IAPT in Autumn Statement to support an increase in access to at least 25% of disease prevalence.

Wellcome supports Prof. David Clark and Prof. Anke Ehlers to investigate how these psychological treatments can be made available to a larger number of people, and how they can be made more effective.

1991

Wellcome contribution

Contributions of others

Outcomes

Impact

2016

Wellcome supports Prof. David Clark through Principal Research Fellowships and Project Grant for the design and testing of psychological therapies.

2007

UK government announces NHS will pioneer the world's largest publicly funded programme of psychological therapies – IAPT, designed, implemented and monitored by Prof. David Clark, delivering many therapies developed through Wellcome funding.

2009

IAPT service launches with 100,000 patients in first year, with expectations to scale up.

2016

After initial launch, IAPT scales up. In 2016, 940,000 patients enter treatment.

2016

UK government announces funding uplift for IAPT in Autumn Statement to support an increase in access to at least 25% of disease prevalence.

Wellcome supports Prof. David Clark and Prof. Anke Ehlers to investigate how these psychological treatments can be made available to a larger number of people, and how they can be made more effective.
What have we learned?

- Wellcome’s contributions to health have primarily been the funding of research and early development of health interventions, including drugs, devices, diagnostics, and cognitive behavioural therapies.

- The average time that has elapsed between first research findings and improved health outcomes has been 10-15 years. Greater focus on the implementation of interventions reduced the time to health impact.

- Wellcome has played a ‘passive’ funder role in supporting research that could have policy relevance – that is, while Wellcome has provided funding, the responsibility for pushing for policy reform required to improve health outcomes has fallen to the investigators.
What could we do differently?

• Diversify Wellcome’s contributions to health-related research beyond just funding – including convening and brokering multi-lateral conversations, advocating for reform, and actively seeking to influence policy.

• Develop an implementation strategy that involves early policy engagement alongside health-related research to facilitate the rapid uptake of research into policy and practice and ensure health interventions can reach the people who could benefit.
Data science methods to assess the influence of scientific research on policy

Dr. Danil Mikhailov
Founder and Head of Wellcome Data Labs
Contents

Context

Team Structure & Focus

Part I: Using ML to understand Reach and Impact
  • Problem Definition
  • Methodology
  • Results
  • Issues
  • Future Development

Part II: Practical Ethics in Product Development
  • Our Ambition
  • What have we achieved?
  • The challenges
  • Acknowledgements
Context
Contextualising this research

• This report is intended as a meta analysis of the approach Wellcome Trust has taken to apply machine learning (ML) to the problem of understanding the reach and influence of Wellcome funded research in Policy.
• Emphasis is on analysing the process, including challenges and issues, rather than publishing the results of that process.
• As such the results are presented unvarnished, following a pilot run of a set of ML tools that are collectively known as the Wellcome Reach tool.
• The results purposefully include errors and duplicates to enable analysis of the cause of the issues and discussion of possible ethical challenges.
• The intention is to iterate the development of the Reach tool until we get the desired accuracy levels and then publish the results.
Team
Who are Wellcome Data Labs?

We are an interdisciplinary team of social scientists, technologists and data scientists founded as an internal start-up in Wellcome in 2017.

We focus on:

• Working on funding data to improve decision making in Wellcome and other funders

• Supporting Wellcome’s Priority Areas on their data and technology needs

• Embedding ethics, social and behavioural analysis into technology and data science work
Data Labs Product Structure

Head of Wellcome Data Labs

Data Infrastructure Product
1 PM
2 developers

Analytics Product
1 PM
2 developers
2 analysts

Reach Tool Product
1 PM
2 developers
1 coordinator

1 Engineering Manager

Data Science Team
1 Data Science Lead, 3 Data Scientists

1 User Researcher

1 Social Sciences Researcher
Problem
Wellcome Success Framework

Ambition 7.
Health is improved through changes in policy and practices.
Ambition 7 - Indicators

a. Policy and practice are informed by research and researchers
   1. Number of policy cases that reference WT funded research
   2. …

b. Decision makers take up Wellcome’s position on policy and practice
   1. Number ..
Finding policy cases: scale justifies use of ML & automation

220,886 documents on WHO website
Methodology
Data Labs approach to collaboration

Setting research question & scope
- Sponsor
- Subject Expert
- Data Scientist
- Analyst

Data Science Stage
- Subject Expert
- Data Scientist
- Analyst

Analysis & Synthesis Stage
- Subject Expert
- Data Scientist
- Analyst

Decision on desired action
- Sponsor
- Subject Expert
- Data Scientist
- Analyst

Outputs
- Theory of Change;
- Research Question;
- Scope;
- Data sources;
- Key words.

Outputs
- Algorithms;
- Tools;
- Raw Data;
- Statistics;
- Enhanced dataset;
- Ranking;
- Tech Report.

Outputs
- Joint Report;
- Case Studies;
- Lessons Learned;
- Academic Paper;
- Questions for further work.

Outputs
- Agreed actions;
- Agreed owners;
- Business Case;
- Deadlines;
- Risks.
Data Science Method

At this stage in the process we take the Theory of Change and other elements agreed with the analysts to begin to create Machine Learning tools and the data pipelines needed to productionise the quantitative analysis.

To understand the reach of Wellcome funded research into policy we created software tools to automatically scrape policy documents from WHO, Unicef, NICE and MSF’s publicly accessible online portals.

Then we developed ML tools using Naïve Bayes to **Find** citation sections in the doc, **Split** them into individual citations, **Parse** them into constituent buckets of “title”, “author”, “date” etc, and **Match** them with a structured dataset of Wellcome funded publications derived from Digital Science’s Dimensions tool.

Please see our tech documentation on [GitHub](https://github.com) for more details and to review code.
Data Science Pipeline

WHO
NICE
Unicef

Digital Science
EPMC

Machine learning
ML accuracy by stage

Find: 85%
Split: 57%
Parse: 87%
Match: 96%
Going from Reach to Influence

The data science work produced a signal which indicates a potential connection between a Wellcome funded publication and a policy document that we define as “reach”.

To get from the weaker claim of “reach” to a stronger claim of “influence” we do a number of follow up steps of more qualitative analysis to validate the claim.

Validation of case studies makes use of multiple methods to clarify the validity of the claimed influence, such as: timeline review, documentation review, consideration of alternative explanations for the observed influence and other independent sources of information.
Preliminary results of Wellcome Reach Tool 1\textsuperscript{st} trial run
## Citations of Wellcome funded publications by policy source

<table>
<thead>
<tr>
<th>Organisation</th>
<th>Documents</th>
<th>WT References*</th>
</tr>
</thead>
<tbody>
<tr>
<td>WHO</td>
<td>7,484</td>
<td>867</td>
</tr>
<tr>
<td>NICE</td>
<td>289</td>
<td>5</td>
</tr>
<tr>
<td>Unicef</td>
<td>189</td>
<td>33</td>
</tr>
<tr>
<td>MSF</td>
<td>69</td>
<td>1</td>
</tr>
</tbody>
</table>

* Results include errors and duplicates, see Issues Section
Issues
Split function causes accuracy issues

Find

85%

Split

57%

Parse

87%

Match

96%
Example: 10 ‘most cited’ papers

The following table shows the ten Wellcome funded papers with the highest number of citations in the Policy document corpus analysed with the Reach Tool. It was initially assumed that the highest cited papers would be best candidates for follow on evaluation.

But:

• 8 out of 10 had duplicate issues (the most striking example is the publication ID 1054751447 – it is supposed to have 56 policy citations and 55 were duplicates).

• 4 out of 10 are false matches (the policy docs do not seem to cite the publication)
<table>
<thead>
<tr>
<th>Case Study ID</th>
<th>#Policycitations</th>
<th>DOI</th>
<th>Publication ID</th>
<th>Right Doi</th>
<th>Title</th>
<th>Policy Tool - Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td>10.1016/s0140-6736(15)</td>
<td>1021970111</td>
<td>10.1016/s0140-6736(15)6/1990â€”2013: a systematic analysis for the Global Burden of Disease Study 2013</td>
<td>Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, for this publication the tool picks up exactly the same policy docs as the different publication below with the same title (Pub ID 1021807036) and none of the policy docs cites this specific publication. (1 policy doc is repeated twice)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>14</td>
<td>10.1016/s0140-6736(15)</td>
<td>1011656620</td>
<td>10.1016/s0140-6736(15)0</td>
<td>Attention deficit hyperactivity disorder</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>9</td>
<td>10.1016/s0140-6736(16)</td>
<td>1004704916</td>
<td>10.1016/s0140-6736(16)3</td>
<td>Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19Â·2 million participants</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>8</td>
<td>10.1016/s1473-3099(10)</td>
<td>1010822696</td>
<td>10.1016/s1473-3099(10)7</td>
<td>Priorities for tuberculosis research: a systematic review</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>8</td>
<td>10.1371/journal.pmed.10</td>
<td>1003600333</td>
<td>10.1371/journal.pmed.10</td>
<td>Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>8</td>
<td>10.7448/ias.15.2.17383</td>
<td>1031727257</td>
<td>10.7448/ias.15.2.17383</td>
<td>Quantifying and addressing losses along the continuum of care for people living with HIV infection in subâ€“Saharan Africa: a systematic review</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>8</td>
<td>10.1371/journal.pmed.10</td>
<td>1011501074</td>
<td>10.1371/journal.pmed.10</td>
<td>Global Estimates of Syphilis in Pregnancy and Associated Adverse Outcomes: Analysis of Multinational Antenatal Surveillance Data</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>56</td>
<td>10.1016/j.trstmh.2007.03</td>
<td>1054751447</td>
<td>10.1016/j.trstmh.2007.03</td>
<td>The treatment of severe malaria</td>
<td></td>
</tr>
</tbody>
</table>

55 same policy doc repeated +1 and they both do not cite the paper
Example: 10 most cited papers (continued)

• It is clear from the results that there is a problem with initial hypothesis that highest-cited papers in the Reach results would make better targets for further evaluation to build evidence of influence. Namely, that many of the highest-cited papers may actually be those with most duplication and accuracy issues. This will require further investigation.

• Nevertheless the Reach tool is finding a significant number of real targets for further evaluation, which the analysts able to confirm 6 of the top 10 highest-cited papers as verified cases of “reach” and suitable for qualitative evaluation.

• The evaluation analysis is instrumental in catching these errors and feeding back into the design of the machine learning method to improve it.
Future
Improvements to ML

• We are working to build a productionised data pipeline that will automatically clean the data coming out of the Reach tools analysis to remove duplicates.

• We are working to increase the accuracy of the 4 stages of ML and have already increased accuracy of the Split step from 57% to 67%. We expect to get this to c. 85% accuracy with current ML approach.

• In a parallel track another member of the team is working on replacing the current Naïve Bayes approach with Neural Nets for all steps, which we will expect to push accuracy of all steps above 90-95%.
Adding Functionality

• Add all text analysis function to find e.g. researchers and institutions using Lucene Search
• Add ability to analyse against sub-categories, such as disease types and document types
• Expand to other Funders and other sources of policy documents and other types of documents like white papers, conference proceedings and panel proceedings
• Integrate with patent and publications analysis tools
• Create a usable front end interface and make tools available as an open service
Releasing the Wellcome Reach Tool as an Open Service
Practical ethics in product development
Our ambition

Blend ethical analysis with data science in practical, lean way that keeps up to speed with product development.

The starting point:

• User researcher collaborates with data scientists to uncover ethical risks.
• Objectivity and deeper layer of analysis is established with the oversight of an external social scientist.
• A working group provides a wider perspectives and keeps things in check.
• Transparency and openness a guiding principle.
Ethical Framework of Thinking for a Product Team

Source of the problem
- Lack of thinking space
- Cognitive and social biases

Product decision making
- User-centred design
- Mitigation & Detection

Thinking space

Algorithm development
- Review for statistical bias
- Check trade-offs for ethical impact

Prevent negative impact

Engagement with the community
- Agreed values
- Embedded awareness in team

Anticipatory ethical analysis
What have we achieved?
Applying creative thinking to generate anticipatory analysis
Using product prioritisation techniques to narrow on highest risks
Online and offline routines to create space for ethical thinking

Analysis

⚠️ Matching Model: Prioritising removing false positives at the expense of also removing true positives.
#352 opened by aoifespenge

⚠️ Is there a need to check for bias on reference components that aren't the title?
#301 opened by aoifespenge

Monthly meetings to review our efforts.
Working group meetings every three months.
Using Github to discuss and prioritize ethical concerns.
Agreeing practical ethical values

Agreed set of ethical values and principles.

Aware of tensions and using them to focus our attention on solving them.
The challenges
Effort versus reward

How do we balance improving the product (eg faster product development; greater accuracy using neural nets) with assuring ourselves that we have sufficiently thought about unintended consequences?

While the point of effort versus reward is always pertinent, the difficult case we have is that we don’t know what we don’t know.

By assuming that research citations is a low risk area (eg compared to finding tumours in medical images) and therefore not putting as much time into anticipating unintended consequences, we run the risk of missing an ethical concern that was not obvious. However, pragmatically we have to draw the line somewhere.
Uncovering bias

It is impossible to remove all bias that could lead to negative consequences, but possible to align the appropriate fairness criteria with the community of people the algorithm system will affect. It is for this reason we have learned that it is important to think of algorithms as one step in a larger system that affects people and build them transparently. Understanding the entire user experience and community map in which the algorithm sits is the key to understanding how best to optimise the algorithm ethically.

Are there opportunities for feedback and correction if the algorithm is found to be inaccurate? How do we communicate to the user what a responsible interpretation of the outputs are?
The question of responsibility for misuse, has been one of the most difficult to answer. If you release a public tool you lose control over how it can be used by others.

For example, if the Reach tool is used to find and target researchers who work in politically controversial areas, like animal testing, which is not an intended use case, what is the responsibility of us as developers to anticipate this?
With thanks to Dr Chonnettia Jones, Jessica Romo, Nick Sorros, Dr Elizabeth Gallagher, Marta Moratti, Sam Depardieu, Hunter Blanks, Aoife Spengeman, Dawn Duhaney, Natalie Leach and Andy Lee.

Please check out our blog at medium.com/wellcome-data-labs
Introduction

As part of the Wellcome Success Framework, the organisation is interested to know whether there is any policy and/or practice influence resulting from its efforts (ambition 7).

Wellcome believes it can influence policy debate and health practice through its pool of grantees. More specifically, it theorises that Wellcome-funded publications and/or grantees can influence policy debate or practice\(^1\) (shared outcome 7a). For instance, a grantee might publish the results of a clinical trial demonstrating that drug X is effective at treating disease Y, which might be picked up by the World Health Organisation (WHO), the UK Ministry of Health or a humanitarian organisation and implemented as new policy and or practice with the aim of improving health outcomes.

The purpose of this document is to outline the evaluation design for shared outcome 7a, building on a thought piece based on Contribution Tracing. Using this approach, some key lines of enquiry and pieces of evidence were identified, which will form the basis of Ambition 7 evaluation efforts as detailed in the evaluation matrix below.

Approach and methodology

The top 10 most cited Wellcome publications will be chosen to pilot this evaluation plan, using a positive deviance approach. Below are the main lines of enquiry:

1) **Clarifying and confirming Wellcome’s contribution to the research publication and body of knowledge.**

The first step is to establish and confirm that Wellcome funded (fully or partially) the work that supports the research publication’s content.

---

\(^1\) This is in line with research uptake theories and work by ODI (see RAPID and ROMA areas of work) and DFID’s research uptake guidance (2016), to name some sources.
In some cases, the publication acknowledges Wellcome and clarifies the grant supporting it. In other cases, the link with Wellcome is less apparent and requires more investigation. Moreover, we need to establish how the grant contributed to this specific research publication. The publication might be a direct output of the grant or, more often, a collection of multiple inputs and contribution and the Wellcome grant is one of many of them. As the specific contribution of each part is often difficult to establish from looking at the publication itself, this step often requires contacting the grantee and clarifying how the Wellcome-funded contribution is reflected in the content of the publication.

According to Start and Hovland (p8, 2014) it is important to understand what is unique or “how divergent is the new evidence” generated for policy influence. Therefore, the exact health-related issue covered by Wellcome-funded research and the contribution made to the existing body of knowledge will be summarised for selected cases.

2) Clarifying and confirming the research publication’s use by policy or health stakeholders

Once we are confident that the research publication has been supported by Wellcome, we investigate whether the grantee had undertaken any activities to expose the research outputs to policy makers and how the Wellcome grants contributed to the policy or health publication where it has been cited. When available, we checked internal records and reports of the grant and report whether they undertook, during the grant period, any relevant policy activities.

We then use the REACH tool, developed by the Wellcome DataLabs team, to find out how many times and in which policy documents the publication is cited. We skimmed all the policy documents identified by the REACH tool and count and categorise all the citations found within each document.

We classify each citation found as “supporting” and “mentioning” or “contradicting”. We classified a citation as “supporting” if evidence from the publication is used to inform a finding and/or recommendation. “Mentioning” if the publication is mentioned to give context, background or set the scene for analysis. “Contradicting” if the publication is disproved or disagreed with in the policy document.

3) Overall assessment of the publication’s influence on policy

We use the analysis of the citations, to infer on the overall influence of the publication on policy. We categorise policy influence or health impact based on the typology developed by Jones and Villar, 2008; Keck and Sikkink, 1998:

- **Framing debates and getting issues on to the political agenda**, which is thought to be caused by changes in awareness, attitudes or perceptions of key stakeholders.

---

2 For example, the grant reference could be missing or misreported. We investigate whether the reference is correct by checking internal records and/or contacting directly the grantee/grantees that might have been the ones reporting the reference.

3 This step includes reading and summarising the research publication (mostly abstract, background and conclusions) to capture how the publication fits and expands the existing body of knowledge.
• **Influencing discourse and commitments** from states and other policy actors, affecting language and rhetoric to, for example, declare that a new strain of virus is a global priority that should be urgently funded through the WHO.

• **Procedural change** at domestic or international level (i.e. changes in the way policy decisions are made). For example, a new requirement for policy development is to have a series of formal consultations with researchers and other thematic experts, to better inform policy.

• **Legislative change** (i.e. new policy) or change in guidelines and practice\(^4\).

• **Behaviour change** of key actors, such as policy implementation.

### 4) Validation and triangulation

To make sure that the contribution statements are valid and accurate (both the Wellcome’s contribution to the publication as well as the publication’s contribution to policy), we share the draft contribution narrative with the Wellcome grantee, the grant manager (when appropriate) and a co-author (or main author) of the research paper. We ask the first two stakeholders to comment and confirm the draft narrative.

For external validation, we ask three/four questions to one external stakeholder, knowledgeable of the issue and familiar with the policy debate around the issue:

- To what extent do you agree with the description of the outcome?
- To what extent do you agree with the description of Wellcome’s contribution?
- To what extent do you agree with the description of the publication’s contribution?
- To what extent do you agree with the description of the significance of the outcome?

The respondent states if s/he 1) fully agree 2) partially agree 3) disagree and the reasons for his/her response.

### 5) Final assessment on significance of the Wellcome and publication’s contribution is revised/finalised.

In light of the validation and triangulation, the narrative and overall assessment is revised and finalised.

The matrix below details indicators, methodologies and source of information for the above.

---

\(^4\) We include in this category findings that influence changes in WHO guidelines. While not formally mandatory, guidelines have a strong influence on expected practice.
<table>
<thead>
<tr>
<th>Key Evaluation questions</th>
<th>Indicators</th>
<th>Method</th>
<th>Sources</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dimension: Contribution Claim</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. Are policy/health citations from research publications that were funded by Wellcome?</td>
<td>1.1 Grant records of Wellcome funding that corroborate publication as a result of this funding (i.e. application and end of grant report) or 1.2 Grantee’s confirmation of Wellcome’s grant supporting the research output. 1.3 Publications acknowledge Wellcome as funder and/or specify grant ID. 1.4 Lead author/grantee’s clarification on grant’s contribution to the research publication</td>
<td>• Document review  • Desk review  • Email exchange</td>
<td>1. Reach tool 2. Grant Tracker 3. Email 4. End of Grant report</td>
</tr>
<tr>
<td>2. What is unique or “how divergent is the new evidence” generated?</td>
<td>2.1 Peer-reviewed publication detailing contribution to body of knowledge</td>
<td>• Documentation review  • Desk review</td>
<td>5. Europe PubMed Central</td>
</tr>
<tr>
<td><strong>Dimension: Research reach/use</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Are Policy makers/intermediaries exposed to Wellcome-funded grantees and/or their research findings?</td>
<td>3.1 Number and type of citations of Wellcome publications in policy or practice documents; 3.2 Relevance and prominence of citation vis a vis knowledge produced by Wellcome’s grantees and other citations. 3.3 Researchers reporting policy engagement activity</td>
<td>• Document review</td>
<td>1. Reach tool (Uber dimension) 2. Review of citations within policy documents</td>
</tr>
<tr>
<td><strong>Dimension: Overall influence</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. What type of overall contribution we can infer?</td>
<td>4.1 Overall assessment on type of policy influence or health impact</td>
<td>Author’s assessment using typology developed by Jones and Villar, 2008; Keck and Sikkink.</td>
<td></td>
</tr>
<tr>
<td><strong>Dimension: Validation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Is Policy debate and/or practice informed by Wellcome-funded grantees and/or research?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5.1 Grantee’s clarification on research publication’s influence on policy and or practice paper where it was cited</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5.2 Independent but knowledgeable stakeholder(s) agrees on:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- the description of the outcome</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- the description of Wellcome’s contribution (if known)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- the description of the publication’s contribution</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- the description of the significance of the outcome</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dimension: Revision and finalisation of contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>6. In light of the results from dimension 5, can we confirm analysis and contribution story?</td>
</tr>
<tr>
<td>6.1 Revision and finalisation of the contribution story</td>
</tr>
</tbody>
</table>

- Email questionnaire
- Wellcome grantees
- Grant manager
- Independent external informant